Drug
Galvokimig
Galvokimig: highest development phase Phase 2, developed by UCB. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- UCB
Trials
| Drug | Phase | Indication |
|---|---|---|
| Galvokimig NCT07725939 | Phase 2 | Chronic Obstructive Pulmonary Disease With Chronic Bronchitis |
| Galvokimig NCT07720375 | Phase 2 | Non-cystic Fibrosis Bronchiectasis |
| Galvokimig NCT07277660 | Phase 2 | Atopic Dermatitis |
Latest
No recent events.
Follow Galvokimig on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.